The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real‐life settings

It is important to investigate the treatment outcomes in patients excluded from clinical trials (CTR). The aims of this study were to evaluate the efficacy and safety of a 24‐week daclatasvir (DCV) and asunaprevir (ASV) therapy for patients with chronic hepatitis C virus (HCV)‐1b infection.

[1]  H. Nomura,et al.  Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75 years and over with or without cirrhosis , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

[2]  J. Bruix,et al.  Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. , 2016, Journal of hepatology.

[3]  Yoshiyuki Suzuki,et al.  Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. , 2016, Journal of medical virology.

[4]  J. Kao,et al.  All‐oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub‐analysis in Asian patients from the HALLMARK DUAL study , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[5]  K. Chayama,et al.  Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b–infected Japanese patients with or without cirrhosis , 2015, Hepatology.

[6]  M. Imamura,et al.  Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader Assay , 2015, PloS one.

[7]  T. Ide,et al.  Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. , 2015, The Lancet. Infectious diseases.

[8]  Yoshiyuki Suzuki,et al.  Evolution of simeprevir‐resistant variants in virological non‐responders infected with HCV genotype 1b , 2015, Journal of medical virology.

[9]  N. Enomoto,et al.  Deep Sequencing and Phylogenetic Analysis of Variants Resistant to Interferon-Based Protease Inhibitor Therapy in Chronic Hepatitis Induced by Genotype 1b Hepatitis C Virus , 2015, Journal of Virology.

[10]  K. Chayama,et al.  Randomized trial of interferon‐ and ribavirin‐free ombitasvir/paritaprevir/ritonavir in treatment‐experienced hepatitis C virus–infected patients , 2015, Hepatology.

[11]  S. Mochida,et al.  A Novel Simple Assay System to Quantify the Percent HCV-RNA Levels of NS5A Y93H Mutant Strains and Y93 Wild-Type Strains Relative to the Total HCV-RNA Levels to Determine the Indication for Antiviral Therapy with NS5A Inhibitors , 2014, PloS one.

[12]  F. Kondo,et al.  Discrimination of fibrotic staging of chronic hepatitis C using multiple fibrotic markers , 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

[13]  N. Hayashi,et al.  Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study , 2014, Journal of Gastroenterology.

[14]  Stefan Zeuzem,et al.  Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. , 2014, The New England journal of medicine.

[15]  K. Chayama,et al.  Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection , 2014, Hepatology.

[16]  M. Manns,et al.  Once‐daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment‐naïve genotype 1 hepatitis C: The randomized PILLAR study , 2013, Hepatology.

[17]  Kenji Ikeda,et al.  Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. , 2013, Journal of hepatology.

[18]  N. Meanwell,et al.  Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032) , 2012, Antimicrobial Agents and Chemotherapy.

[19]  Yoshiyuki Suzuki,et al.  Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. , 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[20]  N. Hayashi,et al.  Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. , 2012, Journal of hepatology.

[21]  S. Locarnini,et al.  Hepatitis C virus resistance to protease inhibitors. , 2011, Journal of hepatology.

[22]  C. Schiffer,et al.  Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding , 2010, Proceedings of the National Academy of Sciences.

[23]  Min Gao,et al.  Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System , 2010, Antimicrobial Agents and Chemotherapy.

[24]  Min Gao,et al.  Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect , 2010, Nature.

[25]  Murashima,et al.  Distinction between chronic hepatitis and liver cirrhosis in patients with hepatitis C virus infection. Practical discriminant function using common laboratory data. , 2000, Hepatology research : the official journal of the Japan Society of Hepatology.